<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13</volume><submitter>Ye X</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Gasdermin D (GSDMD) plays an essential role in the pathway of pyroptosis. However, whether GSDMD participates in myocardial ischaemia/reperfusion injury (MI/RI) remains poorly understood.&lt;h4>Methods&lt;/h4>Serum levels of GSDMD and IL-18 in ST-segment elevation myocardial infarction (STEMI) patients were measured by ELISA. The expression of GSDMD and GSDMD N-terminal (GSDMD-NT) &lt;i>in vivo&lt;/i> and &lt;i>in vitro&lt;/i> was assessed by western blot and immunofluorescence staining. GSDMD&lt;sup>-/-&lt;/sup&gt; mice and wild type (WT) mice were induced MI/RI, followed by cardiac ultrasound and histological analysis.&lt;h4>Results&lt;/h4>Clinically, patients suffering from STEMI after percutaneous coronary intervention (PCI) exhibited higher levels of GSDMD and IL-18 than that in the controls. &lt;i>In</pubmed_abstract><journal>Frontiers in immunology</journal><pagination>893914</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9546776</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>GSDMD contributes to myocardial reperfusion injury by regulating pyroptosis.</pubmed_title><pmcid>PMC9546776</pmcid><pubmed_authors>Wu Z</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Hu W</pubmed_authors><pubmed_authors>Xu C</pubmed_authors><pubmed_authors>Ju D</pubmed_authors><pubmed_authors>Ye X</pubmed_authors><pubmed_authors>Luan J</pubmed_authors><pubmed_authors>Zhang P</pubmed_authors></additional><is_claimable>false</is_claimable><name>GSDMD contributes to myocardial reperfusion injury by regulating pyroptosis.</name><description>&lt;h4>Background&lt;/h4>Gasdermin D (GSDMD) plays an essential role in the pathway of pyroptosis. However, whether GSDMD participates in myocardial ischaemia/reperfusion injury (MI/RI) remains poorly understood.&lt;h4>Methods&lt;/h4>Serum levels of GSDMD and IL-18 in ST-segment elevation myocardial infarction (STEMI) patients were measured by ELISA. The expression of GSDMD and GSDMD N-terminal (GSDMD-NT) &lt;i>in vivo&lt;/i> and &lt;i>in vitro&lt;/i> was assessed by western blot and immunofluorescence staining. GSDMD&lt;sup>-/-&lt;/sup&gt; mice and wild type (WT) mice were induced MI/RI, followed by cardiac ultrasound and histological analysis.&lt;h4>Results&lt;/h4>Clinically, patients suffering from STEMI after percutaneous coronary intervention (PCI) exhibited higher levels of GSDMD and IL-18 than that in the controls. &lt;i>In</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2026-05-31T16:06:56.073Z</modification><creation>2025-02-19T01:28:03.415Z</creation></dates><accession>S-EPMC9546776</accession><cross_references><pubmed>36217543</pubmed><doi>10.3389/fimmu.2022.893914</doi></cross_references></HashMap>